Warfarin or excipient allergy: a clinical dilemma resolved

Mitchell J Gooch, Ngozichukwuka L Okiwelu, Timothy Law, Andrew P McLean-Tooke and Pragnesh Joshi
Med J Aust 2015; 203 (5): . || doi: 10.5694/mja15.00084
Published online: 7 September 2015

A 57-year-old Asian woman was referred for surgical ablation of atrial fibrillation (AF), coronary revascularisation and mitral valve surgery. She had a history of paroxysmal AF, previous stroke, coronary artery disease and severe mitral regurgitation. In the work-up for surgery, she developed recurrent, pruritic maculopapular rashes involving her trunk and upper limbs on two occasions within 3 days of initiating oral anticoagulation with warfarin (Marevan, Aspen) for AF. There were no other changes to the patient’s longstanding medication regimen during this period. Her regular medications consisted of aspirin 100 mg and perindopril arginine 2.5 mg in the morning, and atorvastatin 80 mg at night. Long-term anticoagulation with warfarin was necessary due to planned mechanical valve replacement and ongoing paroxysmal AF. Subsequently, she was referred to a clinical immunologist for assessment of her reaction to warfarin. Since allergic reactions to warfarin are rare, a reaction to one of the dyes in the tablet was considered.

  • 1 Sir Charles Gairdner Hospital, Perth, WA
  • 2 Fiona Stanley Hospital, Perth, WA
  • 3 PathWest Laboratory Medicine, Perth, WA



We thank David Lui, Senior Pharmacist at Sir Charles Gairdner Hospital, for his assistance.

Competing interests:

No relevant disclosures.

  • 1. Bogart MA, Cheema A, Wooten JM, Bogart DB. Warfarin allergy: an easy solution. Clin Cardiol 2010; 33: E31-E32.
  • 2. Swerlick RA, Campbell CF. Medication dyes as a source of drug allergy. J Drugs Dermatol 2013; 12: 99-102.
  • 3. Syed NB, Marktanner R, Gharaibeh D. Warfarin-induced pseudo-allergy. J Hematol 2014; 3: 116-117.
  • 4. Magner J, Gerber P. Urticaria due to blue dye in synthroid tablets. Thyroid 1994; 4: 341.
  • 5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.